Novartis Institutes Enterprise Account Executive Salaries in Boston
The average Novartis Institutes Enterprise Account Executive in Boston earns an estimated $115,097 annually, which includes an estimated base salary of $74,877 with a $40,220 bonus. Novartis Institutes' Enterprise Account Executive compensation is $1,623 more than the US average for a Enterprise Account Executive. Enterprise Account Executive salaries at Novartis Institutes in Boston can range from $43,867 - $152,000.
In Boston, The Business Development Department at Novartis Institutes earns $5,297 more on average than the Finance Department.
Last updated 2 years ago.
- $74,877
- avg. base
- $40,220
- avg. bonus
Enterprise Account Executive Salaries at Novartis Institutes
In Boston, Enterprise Account Executives earn $8,011 more than Account Managers, and $17,793 less than Business Development Managers.
Compensation at Novartis Institutes by Department
In Boston, The Business Development Department averages $5,297 more than the Finance Department, and $17,425 less than the HR Department
Enterprise Account Executive Compensation by Gender (All Companies)
The average female Enterprise Account Executive at companies similar size to Novartis Institutes reported making $102,479, while the average male Enterprise Account Executive at similar sized companies reported making $94,544.
Enterprise Account Executive Compensation by Ethnicity (All Companies)
The average Asian or Pacific Islander Enterprise Account Executive at companies similar size to Novartis Institutes reported making $111,125, while the average Native American Enterprise Account Executive at similar sized companies reported making $50,000.
How Enterprise Account Executives at Novartis Institutes Rate Their Compensation
The majority of Enterprise Account Executives at Novartis Institutes believe they're compensated fairly. 100% of Enterprise Account Executives at Novartis Institutes say they receive annual bonuses, and the vast majority (100%) are satisfied with their benefits. See more compensation ratings at Novartis Institutes
